Trodelvy

(Sacituzumab)

ApprovedMonoclonal antibody

Sacituzumab is used to treat certain types of cancer, including triple-negative breast cancer and urothelial cancer. It works by targeting cancer cells and delivering a toxic substance directly to them to kill the cancer.[2] Trodelvy is currently approved and in use across 66 indications[4].[1]

Trodelvy is one of 972 small molecule programs targeting Bladder Cancer. It is currently in Approved.

Indications

178

Total Trials

157

Active Trials

971

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Bladder CancerRecruiting

CholangiocarcinomaActive, not recruiting

ThymomaRecruiting

Differentiated Thyroid CancerRecruiting

SacituzumabRecruiting

Advanced Triple Negative Breast CancerRecruiting

Urinary Bladder CancerActive, not recruiting

Recurrent Lung Non-Small Cell CarcinomaRecruiting

Breast CancerRecruiting

Advanced or Metastatic Solid TumorRecruiting

Bladder CancerPhase 2

Recruiting

CholangiocarcinomaPhase 2

Active, not recruiting

ThymomaPhase 2

Recruiting

Differentiated Thyroid CancerPhase 2

Recruiting

SacituzumabPhase 2

Recruiting

Advanced Triple Negative Breast CancerPhase 2

Recruiting

Urinary Bladder CancerPhase 2

Active, not recruiting

Recurrent Lung Non-Small Cell CarcinomaPhase 2

Recruiting

Breast CancerPhase 2

Recruiting

Advanced or Metastatic Solid TumorPhase 1

Recruiting

Showing 10 of 66 indications

Competition

Competitive Landscape

702 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Trodelvy

Gilead

Approved

35 2

Lexiscan

Astellas

Preclinical

1 3

Voltaren

Novartis

Preclinical

1 4

Blenoxane

Bristol-Myers Squibb

Preclinical

1 5

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 6

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

Chantix

PPrism Pharmaceuticals

Preclinical

1 8

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 9

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 10

Tianeptine

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Breast Cancer

NCT04639986

Phase 2Active, not recruiting

Metastatic Solid Tumors

NCT03964727

Phase 2Recruiting

Urothelial Carcinoma

NCT06682728

Phase 1Recruiting

Advanced or Metastatic Solid Tumor

NCT04617522

Phase 1Not yet recruiting

Breast Cancer

NCT07163481

Phase 2Recruiting

Non-Small Cell Lung Cancer

NCT07323056

Clinical

Trials by Indication[1]

Breast Cancer35 trials

Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

Active, not recruiting·PPeking University Cancer Hospital & Institute··NCT07018427·70 enrolled

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Terminated·GG1 Therapeutics, Inc.·Phase 2·NCT05113966·30 enrolled

Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Active, not recruiting·SSWOG Cancer Research Network·Phase 2·NCT04647916·44 enrolled

Show 32 more trials

Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer

Active, not recruiting·UUniversity of Kansas Medical Center·Phase 1·NCT05143229·18 enrolled

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT06238921·31 enrolled

Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Active, not recruiting·GGBG Forschungs GmbH·Phase 3·NCT04595565·1,332 enrolled

Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer

Not yet recruiting·FFudan University·Phase 2·NCT07368543·216 enrolled

SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer

Not yet recruiting·WWest China Hospital·Phase 2·NCT07109284·55 enrolled

Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer

Recruiting·GGuangzhou Medical University·Phase 1/2·NCT06462092·34 enrolled

Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 1/2·NCT07139470·59 enrolled

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

Active, not recruiting· Gilead logo

Gilead·Phase 3·NCT04639986·331 enrolled

Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer

Recruiting·FFudan University·Phase 2·NCT07471776·45 enrolled

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

Active, not recruiting· Gilead logo

Gilead·Phase 3·NCT05840211·654 enrolled

Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases

Not yet recruiting·GGuangzhou Medical University·Phase 2·NCT06462079·43 enrolled

Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer

Not yet recruiting·MMedSIR·Phase 2·NCT07367178·30 enrolled

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

Not yet recruiting·MMediLink Therapeutics (Suzhou) Co., Ltd.·Phase 3·NCT07461454·376 enrolled

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT06409390·15 enrolled

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

Active, not recruiting·—·Phase 2·NCT06100874·28 enrolled

Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer

Recruiting·YYeon Hee Park·Phase 2·NCT06616987·40 enrolled

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

Recruiting·GGerman Cancer Research Center·Phase 2·NCT05332561·240 enrolled

Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07153965·47 enrolled

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

Completed· Gilead logo

Gilead·Phase 3·NCT03901339·543 enrolled

HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan

Recruiting·SSOLTI Breast Cancer Research Group·Phase 2·NCT06236269·50 enrolled

Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study

Recruiting·PPeking University Cancer Hospital & Institute··NCT07251868·100 enrolled

A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors

Not yet recruiting·HHunan Cancer Hospital·Phase 1·NCT07163481·12 enrolled

Real-world Effectiveness and Safety Study of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer

Recruiting·FFudan University··NCT06356519·150 enrolled

Organoid-based Functional Precision Therapy for Advanced Breast Cancer

Recruiting·GGuangdong Provincial People's Hospital·Phase 2·NCT06102824·252 enrolled

Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer

Recruiting·BBritish Columbia Cancer Agency·Phase 2·NCT06665178·20 enrolled

HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 1/2·NCT06328387·120 enrolled

Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED

Completed·MMedSIR·Phase 2·NCT05520723·50 enrolled

Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration

Recruiting·PPeking University Cancer Hospital & Institute··NCT06991790·51 enrolled

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Recruiting·LLaura Huppert, MD, BA·Phase 2·NCT03971409·150 enrolled

SERIES: SEquencing Sacituzumab Govitecan AfteR T-DXd In ER+/HER2 LOW/ULTRA LOW MetaStatic Breast Cancer

Recruiting·RReshma L. Mahtani, D.O.·Phase 2·NCT06263543·75 enrolled

NeoAdjuvant Dynamic Marker - Adjusted Personalized Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer

Not yet recruiting·WWest German Study Group·Phase 3·NCT07178730·765 enrolled

Phase 1b/2 Study to Evaluate Antibody-Drug Conjugate Sacituzumab Govitecan in Combination With PARP Inhibitor Talazoparib in Patients With Metastatic Breast Cancer

Active, not recruiting·MMassachusetts General Hospital·Preclinical·NCT04039230·75 enrolled

Triple-Negative Breast Cancer13 trials

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

Recruiting· Gilead logo

Gilead·Phase 1/2·NCT06926920·100 enrolled

Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

Active, not recruiting· Gilead logo

Gilead·Phase 2·NCT04454437·80 enrolled

Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Terminated· Gilead logo

Gilead·Phase 2·NCT04958785·92 enrolled

Show 10 more trials

Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)

Completed· Gilead logo

Gilead·Phase 3·NCT02574455·529 enrolled

A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)

Not yet recruiting·YYantai Yuhuangding Hospital·Phase 2·NCT07054242·52 enrolled

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05675579·27 enrolled

A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies

Terminated·IImmunityBio, Inc.·Phase 1/2·NCT04927884·3 enrolled

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Active, not recruiting· Gilead logo

Gilead·Phase 3·NCT05382286·443 enrolled

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Active, not recruiting· Gilead logo

Gilead·Phase 3·NCT05382299·623 enrolled

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

Recruiting· Gilead logo

Gilead·Phase 3·NCT05633654·1,514 enrolled

A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06393374·1,530 enrolled

NeoAdjuvant Dynamic Marker - Adjusted Personalized Therapy Comparing Sacituzumab Govitecan Versus Sacituzumab Govitecan+Pembrolizumab in Low-risk, Triple-negative Early Breast Cancer (ADAPT-TN-III)

Recruiting·WWest German Study Group·Phase 3·NCT06081244·348 enrolled

ISIdE: Open Label, Multicentric, Single-arm Phase IIIB Trial to Evaluate the Safety and Efficacy of Sacituzumab Govitecan in Triple Negative Metastatic Breast Cancer Patients With a Biomarker Analysis

Active, not recruiting·UUNICANCER·Phase 3·NCT05552001·96 enrolled

Non-Small Cell Lung Cancer10 trials

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT05609968·614 enrolled

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting· Gilead logo

Gilead·Phase 3·NCT05089734·603 enrolled

A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

Completed· Roche logo

Roche·Phase 1/2·NCT03337698·314 enrolled

Show 7 more trials

Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07244926·31 enrolled

Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer

Recruiting·—·Phase 2·NCT06055465·37 enrolled

Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer

Recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT07323056·36 enrolled

A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06312137·780 enrolled

An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations

Active, not recruiting· Gilead logo

Gilead·Phase 2·NCT05186974·193 enrolled

Phase 1 Trial of MK-2870 as Monotherapy and in Combination With Pembrolizumab ± Chemotherapy in Subjects With Advanced Solid Tumors

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 1·NCT06049212·30 enrolled

A Multicenter, Phase II Clinical Study to Evaluate the Safety and Efficacy of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 2·NCT07329322·30 enrolled

Solid Tumor5 trials

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

Terminated·Ppharmaand GmbH·Phase 1/2·NCT03992131·25 enrolled

Study of Sacituzumab Govitecan in Patients With Solid Tumor

Active, not recruiting· Gilead logo

Gilead·Phase 2·NCT05119907·53 enrolled

A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-021 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors

Recruiting·AAvenzo Therapeutics, Inc.·Preclinical·NCT05867251·430 enrolled

Show 2 more trials

A Phase 1 Study to Evaluate the Safety and Tolerability of GS-0201 as Monotherapy and in Combination in Adults With Advanced Solid Tumors

Recruiting· Gilead logo

Gilead·Phase 1·NCT06167317·278 enrolled

A Phase 1/2 Open-Label Study of Sacituzumab Govitecan in Japanese Patients With Advanced Solid Tumors (ASCENT-J02)

Active, not recruiting· Gilead logo

Gilead·Preclinical·NCT05101096·135 enrolled

Cervical Cancer5 trials

A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer

Not yet recruiting·ZZheng Min·Phase 2·NCT07348861·25 enrolled

SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT07256236·89 enrolled

A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as Firstline Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT07216703·1,023 enrolled

Show 2 more trials

A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06459180·686 enrolled

A Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate in Patients With Recurrent or Persistent Cervical Cancer

Recruiting·YYale University·Phase 2·NCT05838521·20 enrolled

79 more indications

Bladder Cancer5 trials

Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer

Not yet recruiting·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT06528483·63 enrolled

Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer

Recruiting·UUniversity of Washington·Phase 2·NCT05581589·18 enrolled

Drug Screening Using IMD in Bladder Cancer

Unknown status·—·Phase 1·NCT06204614·18 enrolled

Show 2 more trials

Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer

Recruiting·IIRCCS San Raffaele·Phase 2·NCT05226117·44 enrolled

A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigator's Choice of Non-platinum Chemotherapy in Participants With Pretreated Locally Advanced/Metastatic Urothelial Carcinoma

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT07419295·590 enrolled

Esophageal Squamous Cell Carcinoma4 trials

A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

Not yet recruiting·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT07128693·60 enrolled

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06E

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06780111·298 enrolled

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06B

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT05319730·230 enrolled

Show 1 more trial

A Phase II Study of Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma Patients

Recruiting·NNational Taiwan University Hospital·Phase 2·NCT06329869·35 enrolled

Urothelial Carcinoma4 trials

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence

Recruiting·UUniversity of California, Irvine·Phase 2·NCT06682728·23 enrolled

Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients

Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT04863885·46 enrolled

A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT06483334·38 enrolled

Show 1 more trial

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Terminated· Roche logo

Roche·Preclinical·NCT03869190·272 enrolled

Ovarian Cancer4 trials

Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer

Not yet recruiting·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT07314619·30 enrolled

A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients

Active, not recruiting·YYale University·Phase 2·NCT06028932·20 enrolled

A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06824467·770 enrolled

Show 1 more trial

A Single-Center, Open-Label, Single-Arm, Phase I Study With Dose Expansion Cohort of Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

Recruiting·IIcahn School of Medicine at Mount Sinai·Preclinical·NCT06040970·54 enrolled

Sacituzumab Tirumotecan3 trials

Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC

Not yet recruiting·XXijing Hospital·Phase 2·NCT07007780·35 enrolled

Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC

Recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT07088211·39 enrolled

Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC

Not yet recruiting·—·Phase 2·NCT07388875·30 enrolled

Non-small Cell Lung Cancer (NSCLC)3 trials

A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06170788·614 enrolled

A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06305754·550 enrolled

A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06074588·556 enrolled

Endometrial Cancer3 trials

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

Active, not recruiting· Gilead logo

Gilead·Phase 3·NCT06486441·640 enrolled

A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06952504·1,123 enrolled

A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06132958·710 enrolled

Prostate Cancer2 trials

Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy

Active, not recruiting·UUniversity of Wisconsin, Madison·Phase 2·NCT03725761·31 enrolled

Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)

Recruiting·TTianjin Medical University Second Hospital·Phase 2·NCT07179783·28 enrolled

Thyroid Cancer2 trials

Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)

Recruiting·NNational University Hospital, Singapore·Phase 2·NCT06923826·32 enrolled

Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer

Recruiting·ZZhejiang Provincial People's Hospital·N/A·NCT07068542·94 enrolled

Cholangiocarcinoma2 trials

Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma

Recruiting·SSir Run Run Shaw Hospital·Phase 2·NCT07105852·59 enrolled

Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

Active, not recruiting·UUniversity of Kansas Medical Center·Phase 2·NCT06178588·15 enrolled

Glioblastoma2 trials

Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT03995706·26 enrolled

Sacituzumab Govitecan in Recurrent Glioblastoma

Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT04559230·32 enrolled

Metastatic Solid Tumors2 trials

Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors

Active, not recruiting· Gilead logo

Gilead·Phase 2·NCT03964727·223 enrolled

Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy

Completed· Gilead logo

Gilead·Phase 4·NCT04319198·25 enrolled

Pembrolizumab2 trials

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Recruiting·—·Phase 2·NCT04468061·110 enrolled

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

Active, not recruiting·—·Phase 2·NCT04448886·110 enrolled

Lung Cancer2 trials

Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.

Recruiting·FFundación GECP·Phase 3·NCT06431633·129 enrolled

Study of Novel Treatment Combinations in Patients With Lung Cancer

Recruiting· Gilead logo

Gilead·Phase 2·NCT05633667·270 enrolled

Breast Neoplasms2 trials

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06966700·2,400 enrolled

An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06312176·1,200 enrolled

Triple Negative Breast Neoplasms2 trials

A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less Than 10 (TroFuse-011)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06841354·1,000 enrolled

A Phase 2, Multicenter, Randomized, Open-label Trial Assessing Sacituzumab-govitecan and Trastuzumab-deruxtecan Combinations in an Alternating Regimen for Patients With Metastatic or Locally Advanced HER2-low Triple-negative Breast Cancer

Not yet recruiting·UUNICANCER·Phase 2·NCT07151586·260 enrolled

Lung Neoplasm Malignant2 trials

KEYMAKER-U01 Substudy 01E: A Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With or Without Chemotherapy in Combination With Pembrolizumab in Treatment of Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06788912·60 enrolled

KEYMAKER-U01 Substudy 01F: A Phase 1b/2 Umbrella Study With Rolling Arms of Investigational Agents for Previously Treated Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT07286149·140 enrolled

Gastroesophageal Adenocarcinoma2 trials

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma): Substudy 06C

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06469944·160 enrolled

A Phase 1/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of Investigational Agents in Combination With Standard of Care Treatments as the Second-Line Treatment of Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06445972·210 enrolled

Toripalimab1 trial

Study of Sacituzumab Govitecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLC

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07438600·38 enrolled

Metastatic1 trial

Sacituzumab Govitecan Plus EV in Metastatic UC

Recruiting·—·Phase 1/2·NCT04724018·106 enrolled

Urothelial Cancer1 trial

Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

Completed· Gilead logo

Gilead·Phase 3·NCT04527991·712 enrolled

Advanced or Metastatic NSCLC1 trial

Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy

Not yet recruiting·FFudan University·Phase 2·NCT07193160·45 enrolled

Safety and Efficacy1 trial

Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC

Not yet recruiting·MMedSIR·Phase 2·NCT07134556·25 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma

Not yet recruiting·WWest China Hospital·Phase 2·NCT07492914·30 enrolled

Treatment1 trial

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

Recruiting·TTianjin Medical University Second Hospital·Phase 2·NCT06739395·300 enrolled

Recurrence1 trial

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Recruiting·—·Phase 2·NCT04434040·40 enrolled

Cancer1 trial

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Completed· Gilead logo

Gilead·Phase 1/2·NCT01631552·515 enrolled

Monotherapy1 trial

P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .

Withdrawn·VVeru Inc.·Phase 2·NCT05008510

Mesothelioma1 trial

A Study of Sacituzumab Govitecan in People With Mesothelioma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06477419·33 enrolled

Solid Tumors1 trial

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Recruiting·IIDEAYA Biosciences·Phase 1·NCT04794699·180 enrolled

Patients With Advanced Solid Tumors1 trial

Study of DF1001 in Patients With Advanced Solid Tumors

Completed·DDragonfly Therapeutics·Phase 1/2·NCT04143711·270 enrolled

Cervical Carcinoma1 trial

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT06865677·2 enrolled

Metastatic Colorectal Cancer1 trial

Sacituzumab Govitecan in Metastatic Colorectal Cancer

Recruiting·UUniversity Hospital Heidelberg·Phase 2/3·NCT06243393·80 enrolled

Brain Metastases1 trial

Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

Recruiting·MMaastricht University Medical Center·Phase 2·NCT06401824·25 enrolled

Advanced or Metastatic Solid Tumor1 trial

Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

Recruiting· Gilead logo

Gilead·Phase 1·NCT04617522·30 enrolled

Thymic Epithelial Tumors1 trial

A Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan in Second-Line and Subsequent Treatments for Advanced Thymic Epithelial Tumors

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT07343453·38 enrolled

Metastasis1 trial

Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain Metastasis

Not yet recruiting·LLi-kun Chen·Phase 2·NCT07197008·50 enrolled

Advanced Solid Tumors1 trial

A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

Recruiting·MMarengo Therapeutics, Inc.·Phase 1/2·NCT06827613·50 enrolled

Gastric Adenocarcinoma1 trial

Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma

Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 1/2·NCT06123468·58 enrolled

PD-L1 Positive1 trial

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT07040644·150 enrolled

Intestinal Cancer1 trial

Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy

Recruiting·HHenry Ford Health System·Phase 1·NCT06065371·20 enrolled

Head and Neck Squamous Cell Cancer1 trial

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT07063212·40 enrolled

Advanced1 trial

Trop-2 Targeted PET Probes in Advanced TNBC

Recruiting·PPeking University Cancer Hospital & Institute·N/A·NCT07046455·20 enrolled

Bevacizumab1 trial

Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC

Enrolling by invitation·YYING FAN·Phase 2·NCT07359404·60 enrolled

Endometrial Carcinoma1 trial

A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma

Active, not recruiting·YYale University·Phase 2·NCT04251416·50 enrolled

First-line Treatment1 trial

Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07244874·41 enrolled

TNBC1 trial

Saci Nivo Rela for TNBC

Recruiting·YYale University·Phase 1/2·NCT06963905·60 enrolled

Small Cell Lung Cancer1 trial

Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer

Not yet recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT07328490·120 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Patients With Initially Unresectable Stage III NSCLC

Not yet recruiting·HHunan Province Tumor Hospital·Phase 2·NCT06706219·50 enrolled

Locally Advanced Urothelial Carcinoma1 trial

A Phase III Randomized Trial of Pembrolizumab in Combination With Sacituzumab Govitecan-hziy vs Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT06524544·320 enrolled

Anatomic Stage IV Breast Cancer AJCC v81 trial

Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients With Metastatic Triple Negative Breast Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03606967·86 enrolled

Gland1 trial

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05884320·63 enrolled

Metastatic Bladder Urothelial Carcinoma1 trial

A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT04579224·131 enrolled

Colorectal Cancer1 trial

A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06428409·220 enrolled

Gastroesophageal Cancer1 trial

A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician's Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06356311·473 enrolled

Extensive Stage Small Cell Lung Cancer (ES-SCLC)1 trial

A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Recruiting· Gilead logo

Gilead·Phase 3·NCT06801834·695 enrolled

Advanced Malignant Solid Neoplasm1 trial

Optimizing Antibody-Drug Conjugate Therapy Through Molecular Analysis for Therapy Choice (ADC MATCH)

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06311214·500 enrolled

Small Cell Carcinoma1 trial

A Phase II Study of Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06161532·60 enrolled

Non Muscle Invasive Bladder Cancer1 trial

A Phase 1/2 Open-label Clinical Study to Evaluate the Safety and Efficacy of Intravesical Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06637423·32 enrolled

Ovarian Neoplasms1 trial

A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced Non-HRD Positive Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOTov85/GOG-3102)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT07318558·900 enrolled

Recurrent Lung Non-Small Cell Carcinoma1 trial

A Randomized Phase II Study of Sacituzumab Govitecan Alone, Ivonescimab Alone, or Sacituzumab Govitecan and Ivonescimab in Participants With Previously-Treated Actionable Genomic Alteration Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

Recruiting·SSWOG Cancer Research Network·Phase 2·NCT07393555·117 enrolled

Metastatic Breast Cancer1 trial

A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (Morpheus-panBC)

Recruiting· Roche logo

Roche·Preclinical·NCT03424005·1,132 enrolled

Urinary Bladder Cancer1 trial

An Open Label, Single-arm, Phase 2 Study of Perioperative Sacituzumab Govitecan in Combination With Zimberelimab and Domvanalimab for Patients With Muscle Invasive Bladder Cancer Ineligible for Cisplatin-based Chemotherapy

Active, not recruiting·FFundación para el Progreso de la Oncología en Cantabria·Phase 2·NCT06133517·70 enrolled

Advanced Triple Negative Breast Cancer1 trial

A Phase II Study of First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.

Recruiting·NNathalie Levasseur·Phase 2·NCT07299409·24 enrolled

Locally Advanced or Metastatic Urothelial Carcinoma1 trial

A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination With Other AntiTumor Agents as a Maintenance Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress With First Line Platinum-Containing Chemotherapy (JAVELIN Bladder Medley)

Active, not recruiting· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 2·NCT05327530·256 enrolled

Sacituzumab1 trial

Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07438626·20 enrolled

Differentiated Thyroid Cancer1 trial

A Multicenter, Open Label, Two Cohort, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of the Anti-TROP2 Antibody-drug Conjugate Sacituzumab Govitecan in Patients With Advanced Differentiated and Anaplastic Thyroid Neoplasms.

Recruiting·GGrupo Espanol de Tumores Neuroendocrinos·Phase 2·NCT06235216·42 enrolled

Thymoma1 trial

A Phase II Parallel Arm Study of SACITUZUMAB GOVITECAN-HZIY in Patients With Advanced Thymoma and Thymic Carcinoma

Recruiting·GGeorgetown University·Phase 2·NCT06248515·18 enrolled

Metastatic Urothelial Cancer1 trial

A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer

Active, not recruiting· Gilead logo

Gilead·Phase 2·NCT03547973·502 enrolled

Thymic Carcinoma1 trial

A Phase II Clinical Study of Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma With Treatment Failure After Platinum-Based Therapy

Recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 2·NCT07324629·30 enrolled

Small Cell Lung Cancer ( SCLC )1 trial

Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Recruiting·BBindu R Potugari·Phase 2·NCT07339059·35 enrolled

Metastatic Triple Negative Breast Cancers1 trial

Sacituzumab Tirumotecan to Treat Patients With Brain Metastases From Triple-negative Breast Cancer

Not yet recruiting·YYale University·Phase 2·NCT07458113·20 enrolled

HRD Cancer1 trial

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

Completed·NNational Cancer Institute (NCI)·Preclinical·NCT04826341·35 enrolled

Localized Muscle Invasive Bladder Urothelial Carcinoma1 trial

Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Bladder Preservation in Patients With MIBC (RAD-SG).

Recruiting·SShilpa Gupta, MD·Phase 1·NCT05833867·20 enrolled

Invasive Breast Cancer1 trial

A Phase 2 Study of Response-guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Patients With Localized Triple-Negative Breast Cancer (NeoSTAR)

Recruiting·MMassachusetts General Hospital·Phase 2·NCT04230109·239 enrolled

Solid Malignancies1 trial

A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Subjects With Solid Malignancies

Terminated· Gilead logo

Gilead·Phase 1·NCT05006794·37 enrolled

Metastatic Triple-negative Breast Cancer1 trial

Phase I/II Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

Recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT07011654·31 enrolled

Metastatic HER2-Negative Breast Carcinoma1 trial

A Randomized Clinical Trial Comparing ctDNA-Directed Therapy Change With Standard of Care in Patients With Metastatic Triple Negative Breast Cancer

Recruiting·VVanderbilt-Ingram Cancer Center·Phase 2·NCT05770531·160 enrolled

Unspecified2 trials

StrataPATH™ (Precision Indications for Approved Therapies)

Terminated·SStrata Oncology·Phase 2·NCT05097599·11 enrolled

Scalp Cooling in MBC

Recruiting·—·Phase 2·NCT04986579·120 enrolled

Regulatory

FDA Approval Timeline[5]

Apr 22, 2020

TRODELVY

BLA BLA761115

Sources

References

[1]
ClinicalTrials.gov — 178 trial records for Sacituzumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Trodelvy drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Sacituzumab compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Sacituzumab. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (BLA BLA761115). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Gilead company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[3]
Highest Phase: Approved[1]
Company: Gilead